Home

ECNP 2018

Read time: 3 min

Congress highlights

When to change first-line treatment: Debating an everyday dilemma

If there is partial response after two to four weeks, persist with current therapy. If not, there...

Read time: 4 min

Congress highlights

Dopamine D2 partial agonists – efficacy, tolerability and improved functioning?

‘Functioning’ is a broad term, and encompasses the individual’s ability to...

Improvement in schizophrenia: Long and short term perspectives

Read time: 3 min

Congress highlights

Treating cognitive symptoms improves workplace productivity

The new paradigm for the treatment of major depressive disorder (MDD) is to “make patients...

Read time: 3 min

Congress highlights

Advances towards precision in psychiatry: “Dare, Share and Care”

We are moving towards an era in which treatments are tailored to patient subtypes. Professor Marion...

Read time: 1 min

Professor Mark Opler - Teaming up with patients

Read time: 4 min

Congress highlights

Mechanisms underlying clinical manifestations of treatment resistance in schizophrenia

Antipsychotics are not effective in 30% of patients with schizophrenia. These patients have...

Read time: 4 min

Congress highlights

Niche no more: early use of long-acting injectable antipsychotics in schizophrenia

It is well known that early treatment of schizophrenia leads to better patient outcomes in the long...

Read time: 3 min

Congress highlights

From probiotics to psychobiotics: nutrition, gut and brain

The weight of microbes in our gut is about the same as the weight of our brain. Almost certainly...

Read time: 5 min

Satellite symposium

Can increased focus on patient perspectives improve outcomes in the treatment of schizophrenia?

Discordance between the treatment goals of patients and their clinicians is important, can lead to...

Read time: 4 min

Congress highlights

Functional recovery in depression: are we doing the right thing for the treatment of depression?

Major depressive disorder (MDD) is a heterogeneous disease characterized by many different mood,...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country